 Thiadiazoles
"Thiadiazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013830
|
| MeSH Number(s) |
D02.886.675.867 D03.383.129.708.867
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiadiazoles".
Below are MeSH descriptors whose meaning is more specific than "Thiadiazoles".
This graph shows the total number of publications written about "Thiadiazoles" by people in this website by year, and whether "Thiadiazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 | | 2011 | 3 | 0 | 3 | | 2017 | 1 | 0 | 1 | | 2020 | 3 | 1 | 4 | | 2021 | 2 | 0 | 2 | | 2023 | 1 | 0 | 1 | | 2024 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Thiadiazoles" by people in Profiles.
-
Santoro N. Neurokinin receptor antagonists as potential nonhormone treatments for vasomotor symptoms. Menopause. 2024 Oct 01; 31(10):923-925.
-
Neal-Perry G, Santoro N, Cano A, Nappi RE, Shapiro M, Ottery FD. Totality of evidence refutes neoplasm risk with fezolinetant. Lancet. 2024 05 18; 403(10440):1987-1988.
-
Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Menopause. 2024 Apr 01; 31(4):247-257.
-
Wright AC, Beaudoin FL, McQueen RB, Yeung K, Moradi A, Herron-Smith S, Gutierrez E, Lin GA, Pearson SD. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council. J Manag Care Spec Pharm. 2023 06; 29(6):692-698.
-
Cendra C, Balhorn L, Zhang W, O'Hara K, Bruening K, Tassone CJ, Steinr?ck HG, Liang M, Toney MF, McCulloch I, Chabinyc ML, Salleo A, Takacs CJ. Unraveling the Unconventional Order of a High-Mobility Indacenodithiophene-Benzothiadiazole Copolymer. ACS Macro Lett. 2021 10 19; 10(10):1306-1314.
-
Gummidi L, Kerru N, Ebenezer O, Awolade P, Sanni O, Islam MS, Singh P. Multicomponent reaction for the synthesis of new 1,3,4-thiadiazole-thiazolidine-4-one molecular hybrids as promising antidiabetic agents through a-glucosidase and a-amylase inhibition. Bioorg Chem. 2021 10; 115:105210.
-
Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 12; 27(12):1350-1356.
-
Gummidi L, Kerru N, Awolade P, Raza A, Sharma AK, Singh P. Synthesis of indole-tethered [1,3,4]thiadiazolo and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids as anti-pancreatic cancer agents. Bioorg Med Chem Lett. 2020 11 15; 30(22):127544.
-
Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020 04; 27(4):382-392.
-
Hendry-Hofer TB, Ng PC, McGrath AM, Mukai D, Brenner M, Mahon S, Maddry JK, Boss GR, Bebarta VS. Intramuscular aminotetrazole cobinamide as a treatment for inhaled hydrogen sulfide poisoning in a large swine model. Ann N Y Acad Sci. 2020 11; 1479(1):159-167.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|